CN117960145A - Polyether sulfone microsphere, preparation method and application - Google Patents
Polyether sulfone microsphere, preparation method and application Download PDFInfo
- Publication number
- CN117960145A CN117960145A CN202410023638.0A CN202410023638A CN117960145A CN 117960145 A CN117960145 A CN 117960145A CN 202410023638 A CN202410023638 A CN 202410023638A CN 117960145 A CN117960145 A CN 117960145A
- Authority
- CN
- China
- Prior art keywords
- polyethersulfone
- solution
- microsphere
- polymer
- microspheres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004695 Polyether sulfone Substances 0.000 title claims abstract description 113
- 229920006393 polyether sulfone Polymers 0.000 title claims abstract description 113
- 239000004005 microsphere Substances 0.000 title claims abstract description 109
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 229920000642 polymer Polymers 0.000 claims abstract description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 46
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 36
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000002904 solvent Substances 0.000 claims abstract description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 23
- 238000002156 mixing Methods 0.000 claims abstract description 21
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000003756 stirring Methods 0.000 claims abstract description 11
- WGGNGQYNBZIVDT-UHFFFAOYSA-N C=CC1=NC=CN1.Br Chemical compound C=CC1=NC=CN1.Br WGGNGQYNBZIVDT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 230000001376 precipitating effect Effects 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 104
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 26
- 239000011259 mixed solution Substances 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- IYHLUGVVUPPBEJ-UHFFFAOYSA-N 1-butyl-3-ethenyl-1,2-dihydroimidazol-1-ium;bromide Chemical compound [Br-].CCCC[NH+]1CN(C=C)C=C1 IYHLUGVVUPPBEJ-UHFFFAOYSA-N 0.000 claims description 7
- -1 vinyl imidazole bromine salt Chemical compound 0.000 claims description 7
- 230000005595 deprotonation Effects 0.000 claims description 6
- 238000010537 deprotonation reaction Methods 0.000 claims description 6
- 239000003999 initiator Substances 0.000 claims description 5
- MFWYCCDCCKJJBY-UHFFFAOYSA-N 3-benzyl-1-ethenyl-1,2-dihydroimidazol-1-ium;bromide Chemical compound [Br-].C1=CN(C=C)C[NH+]1CC1=CC=CC=C1 MFWYCCDCCKJJBY-UHFFFAOYSA-N 0.000 claims description 3
- XPGQFVAPXLLSAK-UHFFFAOYSA-N CCCCCCCCN(C1)C=CN1C=C.Br Chemical compound CCCCCCCCN(C1)C=CN1C=C.Br XPGQFVAPXLLSAK-UHFFFAOYSA-N 0.000 claims description 3
- 208000027119 bilirubin metabolic disease Diseases 0.000 claims description 3
- 238000001523 electrospinning Methods 0.000 claims description 3
- 208000036796 hyperbilirubinemia Diseases 0.000 claims description 3
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 abstract description 40
- 238000001179 sorption measurement Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 230000001112 coagulating effect Effects 0.000 description 10
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000010926 purge Methods 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 7
- 239000003463 adsorbent Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- KBOGIATXPIINBP-UHFFFAOYSA-N [Br].C(=C)N1CN(C=C1)CCCC Chemical compound [Br].C(=C)N1CN(C=C1)CCCC KBOGIATXPIINBP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000002467 Acute-On-Chronic Liver Failure Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Landscapes
- Artificial Filaments (AREA)
Abstract
The invention discloses a polyethersulfone microsphere, a preparation method and application, comprising the following steps: step 1: dissolving vinyl imidazole bromide, acrylic acid and azodiisobutyronitrile in a solvent, stirring under the protection of nitrogen, fully reacting, precipitating and filtering to obtain a polymer; step 2: dissolving the polymer obtained in the step 1 in a solvent to obtain a polymer solution; step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution, and obtaining polyethersulfone microspheres through electrostatic spinning; the diameter of the polyethersulfone microsphere is 500-800 mu m, the polyethersulfone microsphere has a loose porous structure, the specific surface area of the microsphere is large, and the bilirubin adsorption effect is good.
Description
Technical Field
The invention relates to the technical field of biological materials, in particular to a polyethersulfone microsphere, a preparation method and application.
Background
Liver failure is a serious liver injury caused by various factors, and causes serious dysfunction or decompensation of synthesis, detoxification, metabolism and bioconversion, and a group of clinical syndrome mainly represented by jaundice, coagulation dysfunction, hepatorenal syndrome, hepatic encephalopathy, ascites and the like appears. Statistics of 2020 indicate that 35% of patients with decompensated liver cirrhosis have a global prevalence of chronic Acute liver failure (Acute-on-chronic liver failure, ACLF) and 58% of patients with 90-day mortality, but not only 14% of patients with ACLF. Data in 2019 shows that about 700 ten thousand patients with cirrhosis exist in China. At present, specific medicines and means are not available for internal medicine treatment of liver failure. In principle, the early diagnosis and early treatment are emphasized, corresponding etiological treatment and comprehensive treatment measures are adopted, and complications are positively prevented and treated. The internal medicine treatment is not effective, liver transplantation is an effective means for treating middle and late stage liver failure patients, liver transplantation is carried out in China for over 40 years, the cumulative number of liver transplantation operations exceeds 20000 cases, and survival rates of liver transplantation patients in 1, 3 and 5 years after the operation reach 84%, 75% and 71% respectively, but due to the common source and economic problems of transplantation, less than 1% of patients have the opportunity to receive liver transplantation treatment. On the basis, the artificial liver support system can temporarily replace partial functions of the failed liver, create conditions for liver cell regeneration and liver function recovery or wait for the opportunity to perform liver transplantation is particularly important.
At present, china mainly adopts a treatment mode of a double plasma molecular adsorption system (Double plasma molecular absorb system, DPMAS), and adopts a combination of two adsorbents, namely neutral macroporous resin (HA 330-II) and ion exchange resin (BS 330), to carry out plasma adsorption treatment. The resin in the HA 330-II hemoperfusion apparatus is a relatively broad-spectrum adsorbent, HAs a macroporous structure and a very large specific surface area, and adsorbs macromolecular toxins in inflammatory factors and the like by virtue of Van der Waals force and the action of a framework molecular sieve. The resin in the BS330 bilirubin absorber is a specific adsorbent for bilirubin, and substances such as bilirubin, bile acid and the like are adsorbed by means of electrostatic acting force and lipophilic binding specificity. When the technology is applied, the treatment mode is complex, the process is complicated, the cost is high, and blood products such as albumin or fresh blood plasma are needed to be supplemented, but at present, domestic blood products are scarce, and the input process can cause the infection of patients with blood-borne diseases, so that the wide clinical application of the various artificial liver systems is limited.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides a polyether sulfone microsphere capable of efficiently adsorbing bilirubin, a preparation method and application thereof.
The invention adopts the technical scheme that:
the preparation method of the polyethersulfone microsphere comprises the following steps:
Step 1: dissolving vinyl imidazole bromide, acrylic acid and an initiator in a solvent to form a mixed solution, stirring under the protection of nitrogen, fully reacting, precipitating and filtering to obtain a polymer; the mol ratio of the vinyl imidazole bromine salt to the acrylic acid is 3-10:1:
Step 2: dissolving the polymer obtained in the step 1 in a solvent to obtain a polymer solution;
step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to form a blend solution, and obtaining polyethersulfone microspheres through electrostatic spinning; wherein the mass ratio of the polymer to the polyethersulfone is 1-4:3.
Further, the reaction temperature in the step 1 is 80 ℃ and the reaction time is 24 hours.
Further, the vinyl imidazole bromide in the step 1 is one of 1-vinyl-3-butyl imidazole bromide, 1-vinyl-3-octyl imidazole bromide and 1-vinyl-3-benzyl imidazole bromide.
Further, the initiator in the step 1 is azobisisobutyronitrile, and the mass concentration of the azobisisobutyronitrile in the mixed solution is 2wt.%.
Further, the coagulating bath solution for electrostatic spinning in the step 3 is ethanol water solution; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 6V-8V.
Further, the mass concentration of the polymer in the blending solution formed in the step 3 is 4 to 16wt.%, and the mass concentration of the polyethersulfone solution is 12wt.%.
Further, the polyether sulfone microsphere obtained by electrostatic spinning in the step 3 is subjected to deprotonation treatment; the deprotonation process is as follows:
The resulting polyethersulfone microspheres were immersed in 0.1M sodium hydroxide solution for 24h.
The polyethersulfone microsphere has a diameter of 500-800 μm, and a loose porous structure is arranged inside the microsphere; the microsphere is internally provided with a tubular hole, and the wall of the tubular hole is provided with micropores.
The application of the polyethersulfone microsphere is characterized in that the polyethersulfone microsphere is applied to the preparation of medical equipment.
Further, the medical device is a device for treating and/or ameliorating hyperbilirubinemia.
The beneficial effects of the invention are as follows:
(1) The diameter of the polyethersulfone microsphere is 500-800 mu m, the polyethersulfone microsphere has a loose porous structure, the specific surface area of the microsphere is large, and the bilirubin adsorption effect can be improved;
(2) The polyethersulfone microsphere has nitrogen positive ions, is combined with bilirubin molecules with negative charges through electrostatic action, and has strong pi-pi conjugated interaction, so that the absorption effect of the polymer microsphere on bilirubin is improved;
(3) The substituent of vinyl imidazole bromide in the polyethersulfone microsphere can form a large number of hydrogen bonds with bilirubin, so that the absorption effect of the adsorbent on bilirubin can be further improved.
Drawings
FIG. 1 is an SEM image of polyethersulfone microspheres obtained in example 7 of the present invention.
FIG. 2 is a schematic view showing the hemolysis result of polyethersulfone microspheres obtained in example 7 of the present invention.
FIG. 3 shows the statistical results of cell activity of polyethersulfone microspheres obtained in example 7 of the present invention after 7 days of co-culture with cells.
FIG. 4 shows the result of fluorescent staining of cells after 7 days of co-culture of polyethersulfone microspheres and cells obtained in example 7 of the present invention.
Detailed Description
The invention will be further described with reference to the drawings and specific examples.
The preparation method of the polyethersulfone microsphere comprises the following steps:
step 1: and (3) dissolving vinyl imidazole bromide, acrylic acid and an initiator azodiisobutyronitrile in a solvent N, N-dimethylformamide to obtain a mixed solution, stirring for 30min at room temperature under nitrogen purging, and reacting for 24h at 80 ℃ under the protection of nitrogen after vacuumizing. The reaction solution was precipitated with acetone, filtered and dried. The vinyl imidazole bromine salt in the step 1 is one of 1-vinyl-3-butyl imidazole bromine salt, 1-vinyl-3-octyl imidazole bromine salt and 1-vinyl-3-benzyl imidazole bromine salt.
The mol ratio of the vinyl imidazole bromine salt to the acrylic acid is 3-10:1; the mass concentration of azobisisobutyronitrile in the mixed solution was 2wt.%.
Step 2: dissolving the polymer (imidazole quaternary ammonium salt polymer) obtained in the step 1 in a solvent N, N-dimethylformamide to obtain a polymer solution;
step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to obtain a blend solution, wherein the mass concentration of the polymer in the blend solution is 4-16 wt%; the mass concentration of the polyethersulfone solution was 12wt.%.
Obtaining polyether sulfone microspheres through electrostatic spinning; the coagulating bath solution of electrostatic spinning is ethanol water solution; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 6V-8V. Wherein the mass ratio of the polymer to the polyethersulfone is 1-4:3.
And carrying out deprotonation treatment on the polyether sulfone microspheres obtained by electrostatic spinning. The deprotonation process is as follows:
The resulting polyethersulfone microspheres were immersed in 0.1M sodium hydroxide solution for 24h.
The polyethersulfone microsphere has a diameter of 500-800 μm, and a loose porous structure is arranged inside the microsphere; the microsphere is internally provided with a tubular hole, and the wall of the tubular hole is provided with micropores.
An application of polyethersulfone microsphere in preparing medical equipment. The medical device is a device for treating and/or ameliorating hyperbilirubinemia. The polyethersulfone microspheres are used as bilirubin adsorbents in blood perfusion apparatus.
Example 1
The preparation method of the polyethersulfone microsphere comprises the following steps:
Step 1: 20mmol of 1-vinyl-3-butyl imidazole bromine salt, 4mmol of acrylic acid and azodiisobutyronitrile are dissolved in 20mL of solvent N, N-dimethylformamide to form a mixed solution, the mass concentration of azodiisobutyronitrile in the mixed solution is 2 wt%, nitrogen is purged and stirred for 30min at room temperature, and the reaction is carried out for 24h under the nitrogen protection condition at 80 ℃ after vacuum pumping. The reaction solution was precipitated with acetone, filtered and dried at 80℃to give a polymer.
Step 2: and (2) dissolving the polymer obtained in the step (1) in a solvent N, N-dimethylformamide to obtain a polymer solution.
Step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to form a blending solution; wherein the mass concentration of polyethersulfone in the blend solution was 12wt.% and the mass concentration of polymer was 4wt.%.
Obtaining polyether sulfone microspheres through electrostatic spinning; the coagulating bath solution for electrostatic spinning is ethanol water solution with volume concentration of 15%; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 6V. The microspheres with the diameter of 500-800 mu M are obtained and soaked in 0.1M sodium hydroxide solution for 24 hours to be deprotonated, thus obtaining the required polyethersulfone microspheres.
Example 2
The preparation method of the polyethersulfone microsphere comprises the following steps:
Step 1: 20mmol of 1-vinyl-3-butyl imidazole bromide, 4mmol of acrylic acid and azodiisobutyronitrile are dissolved in 20mL of solvent N, N-dimethylformamide to form a mixed solution, and the mass concentration of the azodiisobutyronitrile in the mixed solution is 2 wt%; stirring for 30min at room temperature under nitrogen purging, vacuumizing, and reacting at 80 ℃ under nitrogen protection for 24h. The reaction solution was precipitated with acetone, filtered and dried at 80℃to give a polymer.
Step 2: and (3) dissolving the polymer obtained in the step (1) in a solvent N, N-dimethylformamide to obtain a polymer solution.
Step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to form a blending solution; wherein the mass concentration of polyethersulfone in the blend solution is 12wt.% and the mass concentration of polymer is 8wt.%.
Obtaining polyether sulfone microspheres through electrostatic spinning; the coagulating bath solution for electrostatic spinning is ethanol water solution with volume concentration of 15%; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 6V. The microspheres with the diameter of 500-800 mu M are obtained and soaked in 0.1M sodium hydroxide solution for 24 hours to be deprotonated, thus obtaining the required polyethersulfone microspheres.
Example 3
The preparation method of the polyethersulfone microsphere comprises the following steps:
Step 1: 20mmol of 1-vinyl-3-butyl imidazole bromide, 4mmol of acrylic acid and azodiisobutyronitrile are dissolved in 20mL of solvent N, N-dimethylformamide to form a mixed solution, and the mass concentration of the azodiisobutyronitrile in the mixed solution is 2 wt%; stirring for 30min at room temperature under nitrogen purging, vacuumizing, and reacting at 80 ℃ under nitrogen protection for 24h. The reaction solution was precipitated with acetone, filtered and dried at 80℃to give a polymer.
Step 2: and (3) dissolving the polymer obtained in the step (1) in a solvent N, N-dimethylformamide to obtain a polymer solution.
Step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to form a blending solution; wherein the mass concentration of polyethersulfone in the blend solution is 12wt.% and the mass concentration of polymer is 12wt.%.
Obtaining polyether sulfone microspheres through electrostatic spinning; the coagulating bath solution for electrostatic spinning is ethanol water solution with volume concentration of 15%; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 8V. The microspheres with the diameter of 500-800 mu M are obtained and soaked in 0.1M sodium hydroxide solution for 24 hours to be deprotonated, thus obtaining the required polyethersulfone microspheres.
Example 4
The preparation method of the polyethersulfone microsphere comprises the following steps:
Step 1: 20mmol of 1-vinyl-3-butyl imidazole bromide, 4mmol of acrylic acid and azodiisobutyronitrile are dissolved in 20mL of solvent N, N-dimethylformamide to form a mixed solution, and the mass concentration of the azodiisobutyronitrile in the mixed solution is 2 wt%; stirring for 30min at room temperature under nitrogen purging, vacuumizing, and reacting at 80 ℃ under nitrogen protection for 24h. The reaction solution was precipitated with acetone, filtered and dried at 80℃to give a polymer.
Step 2: and (3) dissolving the polymer obtained in the step (1) in a solvent N, N-dimethylformamide to obtain a polymer solution.
Step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to form a blending solution; wherein the mass concentration of polyethersulfone in the blend solution was 12wt.% and the mass concentration of polymer was 16wt.%.
Obtaining polyether sulfone microspheres through electrostatic spinning; the coagulating bath solution for electrostatic spinning is ethanol water solution with volume concentration of 15%; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 7.5V. The microspheres with the diameter of 500-800 mu M are obtained and soaked in 0.1M sodium hydroxide solution for 24 hours to be deprotonated, thus obtaining the required polyethersulfone microspheres.
Example 5
The preparation method of the polyethersulfone microsphere comprises the following steps:
Step 1: 20mmol of 1-vinyl-3-butyl imidazole bromide, 2mmol of acrylic acid and azobisisobutyronitrile are dissolved in 20mL of solvent N, N-dimethylformamide to form a mixed solution, and the mass concentration of the azobisisobutyronitrile in the mixed solution is 2wt.%; stirring for 30min at room temperature under nitrogen purging, vacuumizing, and reacting at 80 ℃ under nitrogen protection for 24h. The reaction solution was precipitated with acetone, filtered and dried at 80℃to give a polymer.
Step 2: and (3) dissolving the polymer obtained in the step (1) in a solvent N, N-dimethylformamide to obtain a polymer solution.
Step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to form a blending solution; wherein the mass concentration of polyethersulfone in the blend solution is 12wt.% and the mass concentration of polymer is 8wt.%.
Obtaining polyether sulfone microspheres through electrostatic spinning; the coagulating bath solution for electrostatic spinning is ethanol water solution with volume concentration of 15%; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 6V. The microspheres with the diameter of 500-800 mu M are obtained and soaked in 0.1M sodium hydroxide solution for 24 hours to be deprotonated, thus obtaining the required polyethersulfone microspheres.
Example 6
The preparation method of the polyethersulfone microsphere comprises the following steps:
Step 1: 30mmol of 1-vinyl-3-butyl imidazole bromide, 2mmol of acrylic acid and azobisisobutyronitrile are dissolved in 20mL of solvent N, N-dimethylformamide to form a mixed solution, and the mass concentration of the azobisisobutyronitrile in the mixed solution is 2wt.%; stirring for 30min at room temperature under nitrogen purging, vacuumizing, and reacting at 80 ℃ under nitrogen protection for 24h. The reaction solution was precipitated with acetone, filtered and dried at 80℃to give a polymer.
Step 2: and (3) dissolving the polymer obtained in the step (1) in a solvent N, N-dimethylformamide to obtain a polymer solution.
Step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to form a blending solution; wherein the mass concentration of polyethersulfone in the blend solution is 12wt.% and the mass concentration of polymer is 8wt.%.
Obtaining polyether sulfone microspheres through electrostatic spinning; the coagulating bath solution for electrostatic spinning is ethanol water solution with volume concentration of 15%; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 6V. The microspheres with the diameter of 500-800 mu M are obtained and soaked in 0.1M sodium hydroxide solution for 24 hours to be deprotonated, thus obtaining the required polyethersulfone microspheres.
Example 7
The preparation method of the polyethersulfone microsphere comprises the following steps:
step 1: 20mmol of 1-vinyl-3-octyl imidazole bromide, 4mmol of acrylic acid and azodiisobutyronitrile are dissolved in 20mL of solvent N, N-dimethylformamide to form a mixed solution, and the mass concentration of the azodiisobutyronitrile in the mixed solution is 2 wt%; stirring for 30min at room temperature under nitrogen purging, vacuumizing, and reacting at 80 ℃ under nitrogen protection for 24h. The reaction solution was precipitated with acetone, filtered and dried at 80℃to give a polymer.
Step 2: and (3) dissolving the polymer obtained in the step (1) in a solvent N, N-dimethylformamide to obtain a polymer solution.
Step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to form a blending solution; wherein the mass concentration of polyethersulfone in the blend solution is 12wt.% and the mass concentration of polymer is 8wt.%.
Obtaining polyether sulfone microspheres through electrostatic spinning; the coagulating bath solution for electrostatic spinning is ethanol water solution with volume concentration of 15%; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 7.5V. The microspheres with the diameter of 500-800 mu M are obtained and soaked in 0.1M sodium hydroxide solution for 24 hours to be deprotonated, thus obtaining the required polyethersulfone microspheres.
Fig. 1 is an SEM image of the polyethersulfone microsphere obtained in this example, and it can be seen from the image that the polyethersulfone microsphere has a diameter of about 500 μm and a porous structure inside, so that the specific surface area of the microsphere can be increased and the adsorption effect can be improved.
FIG. 2 shows the hemolysis results of the polyethersulfone microspheres obtained in the present example, and from the results, the hemolysis results are similar to PES (microspheres obtained by electrospinning only polyethersulfone, namely polyethersulfone microspheres in the prior art), and the biocompatibility is better.
FIG. 3 shows the cell activity results of the polyethersulfone microspheres obtained in the present example after co-culturing with cells for 7 days, the comparative example is PBS solution, and p (VI-8-AA) is the polyethersulfone microspheres obtained in the present example, and as can be seen from the figure, the polyethersulfone microspheres have no obvious toxicity to cells, and are similar to the PBS solution, which indicates that the obtained polyethersulfone microspheres have good biocompatibility.
FIG. 4 shows the result of fluorescent staining of cell activity after 7 days of co-culture of polyethersulfone microspheres and cells obtained in this example, which is consistent with the statistical result of FIG. 3.
Example 8
The preparation method of the polyethersulfone microsphere comprises the following steps:
Step 1: 20mmol of 1-vinyl-3-benzyl imidazole bromide, 4mmol of acrylic acid and azodiisobutyronitrile are dissolved in 20mL of solvent N, N-dimethylformamide to form a mixed solution, and the mass concentration of the azodiisobutyronitrile in the mixed solution is 2 wt%; stirring for 30min at room temperature under nitrogen purging, vacuumizing, and reacting at 80 ℃ under nitrogen protection for 24h. The reaction solution was precipitated with acetone, filtered and dried at 80℃to give a polymer.
Step 2: the polymer obtained in step1 was dissolved in solvent N, N-dimethylformamide to obtain a polymer solution having a mass concentration of 8 wt.%.
Step 3: and (2) mixing the polymer solution obtained in the step (2) and a polyether sulfone solution with the mass concentration of 12wt.% in equal volumes, wherein the mass concentration of the polyether sulfone solution is 12wt.%.
Obtaining polyether sulfone microspheres through electrostatic spinning; the coagulating bath solution for electrostatic spinning is ethanol water solution with volume concentration of 15%; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 6V. The microspheres with the diameter of 500-800 mu M are obtained and soaked in 0.1M sodium hydroxide solution for 24 hours to be deprotonated, thus obtaining the required polyethersulfone microspheres.
The adsorption rate test of bilirubin was performed on the polyethersulfone microspheres obtained in the above example and the polyethersulfone microspheres of the control group (obtained by directly electrospinning with a polyethersulfone solution), and the results are shown in table 1.
The adsorption rate test process is as follows:
Firstly, respectively taking 100mg of samples of each example and control group, then respectively adding the samples into 4mL of PBS solution with bilirubin concentration of 200mg/L, taking 4mL of PBS solution with bilirubin concentration of 200mg/L without the samples as a blank group, and detecting OD438nm by an enzyme-labeled instrument after shaking for 3 hours at 37 ℃ to calculate the adsorption rate.
TABLE 1 bilirubin adsorption rate test results for examples 1-8 and control group
The polyether sulfone microsphere obtained by the invention has nitrogen positive ions after substitution reaction, can be combined with bilirubin molecules with negative charges through electrostatic action, and has strong pi-pi conjugated interaction, so that the absorption effect of the polymer microsphere on bilirubin is improved. The formation of a large number of hydrogen bonds between the substituents of the vinylimidazole bromide salt and bilirubin can also increase the bilirubin adsorption effect of the adsorbent. The polyethersulfone microsphere has selectivity, and the substituent groups of carbon chains with different lengths are combined with bilirubin molecules at different angles, so that the adsorption of other normal components in blood in the cleaning process is reduced. The polyethersulfone microsphere has carboxyl groups, which can improve the blood compatibility of the microsphere and reduce the adhesion of the microsphere to protein in the adsorption process.
Meanwhile, the diameter of the polyethersulfone microsphere is 500-800 mu m, and the inside of the microsphere is of a loose porous structure; the microsphere is internally provided with a tubular hole, and the wall of the tubular hole is provided with micropores. The porous structure increases the specific surface area of the microsphere and improves the adsorption effect.
Claims (10)
1. The preparation method of the polyethersulfone microsphere is characterized by comprising the following steps:
Step 1: dissolving vinyl imidazole bromide, acrylic acid and an initiator in a solvent to form a mixed solution, stirring under the protection of nitrogen, fully reacting, precipitating and filtering to obtain a polymer; the mol ratio of the vinyl imidazole bromine salt to the acrylic acid is 3-10:1:
Step 2: dissolving the polymer obtained in the step 1 in a solvent to obtain a polymer solution;
step 3: blending the polymer solution obtained in the step 2 with a polyethersulfone solution to form a blend solution, and obtaining polyethersulfone microspheres through electrostatic spinning; wherein the mass ratio of the polymer to the polyethersulfone is 1-4:3.
2. The method for preparing polyethersulfone microsphere according to claim 1, wherein the reaction temperature in the step 1 is 80 ℃ and the reaction time is 24 hours.
3. The method for preparing polyethersulfone microsphere according to claim 1, wherein the vinylimidazole bromide in the step 1 is one of 1-vinyl-3-butylimidazole bromide, 1-vinyl-3-octylimidazole bromide and 1-vinyl-3-benzylimidazole bromide.
4. The method for preparing polyethersulfone microspheres according to claim 1, wherein the initiator in the step 1 is azobisisobutyronitrile, and the mass concentration of azobisisobutyronitrile in the mixed solution is 2wt.%.
5. The method for preparing polyethersulfone microspheres according to claim 1, wherein the coagulation bath solution of the electrospinning in the step3 is an aqueous ethanol solution; the injection speed of the electrostatic spinning process is 1.5mm/min, and the voltage is 6V-8V.
6. The method for preparing polyethersulfone microspheres according to claim 1, wherein the mass concentration of the polymer in the blending solution formed in the step 3 is 4-16 wt.%, and the mass concentration of the polyethersulfone solution is 12wt.%.
7. The method for preparing polyethersulfone microspheres according to claim 1, wherein the polyethersulfone microspheres obtained by electrostatic spinning in the step 3 are subjected to deprotonation treatment; the deprotonation process is as follows:
The resulting polyethersulfone microspheres were immersed in 0.1M sodium hydroxide solution for 24h.
8. The polyethersulfone microsphere prepared by the method of any one of claims 1-7, wherein the diameter of the polyethersulfone microsphere is 500-800 μm, and the inside of the microsphere is a loose porous structure; the microsphere is internally provided with a tubular hole, and the wall of the tubular hole is provided with micropores.
9. The use of a polyethersulfone microsphere according to claim 8, wherein the polyethersulfone microsphere is used in the preparation of medical devices.
10. The use of a polyethersulfone microsphere according to claim 9, wherein the medical device is a device for the treatment and/or amelioration of hyperbilirubinemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410023638.0A CN117960145A (en) | 2024-01-08 | 2024-01-08 | Polyether sulfone microsphere, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410023638.0A CN117960145A (en) | 2024-01-08 | 2024-01-08 | Polyether sulfone microsphere, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117960145A true CN117960145A (en) | 2024-05-03 |
Family
ID=90847093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410023638.0A Pending CN117960145A (en) | 2024-01-08 | 2024-01-08 | Polyether sulfone microsphere, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117960145A (en) |
-
2024
- 2024-01-08 CN CN202410023638.0A patent/CN117960145A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103055822B (en) | Blood-purifying adsorbent for clearing blood bilirubin and preparation method thereof | |
| CN102049242B (en) | Anion resin for bilirubin absorption and preparation method thereof | |
| CN104174385B (en) | A kind of adsorbent for bilirubin for blood perfusion | |
| CN105107474B (en) | A kind of chelating type adsorbent and preparation method for blood purification | |
| CN101862610A (en) | Absorption film for eliminating bilirubin and preparation method thereof | |
| CN101298041B (en) | Adsorbing agent for blood perfusion adsorbing bilirubin in vitro and preparation | |
| CN112791712B (en) | Adsorbent for removing protein-bound uremic toxin through blood perfusion and preparation method thereof | |
| CN109513429A (en) | A kind of preparation method of modified adsorbent for bilirubin | |
| CN112871139B (en) | Whole blood perfusion adsorbent, preparation method and application thereof | |
| CN109847719A (en) | A kind of ionic copolymer composite material adsorbent and its preparation method and application | |
| CN103406111A (en) | Adsorbent for removing endotoxin by blood perfusion and preparation method thereof | |
| CN110354820B (en) | Self-anticoagulation blood perfusion adsorbent based on chitosan and carrageenan, and preparation method and application thereof | |
| CN101224413A (en) | Water-soluble cationic polymer adsorption material and applications thereof | |
| CN117960145A (en) | Polyether sulfone microsphere, preparation method and application | |
| CN108889285B (en) | Limited-feeding chromatographic packing, preparation method thereof, stationary phase containing limited-feeding chromatographic packing and application of stationary phase | |
| CN101322932B (en) | Water-soluble polymer adsorption material coupling cyclodextrin and uses thereof | |
| CN109734839A (en) | A kind of high anti-coagulation type polystyrene microsphere and the preparation method and application thereof | |
| WO2020147421A1 (en) | Sugammadex isolation and purification method | |
| CN109794172B (en) | Preparation method of antibacterial hollow fiber membrane for blood purification | |
| CN116966756A (en) | Blood purifying membrane for removing proinflammatory cytokines and preparation method thereof | |
| CN113426423B (en) | Adsorbent for removing LDL (low density lipoprotein) by extracorporeal blood circulation, preparation method thereof and perfusion device | |
| CN114225919B (en) | Endotoxin adsorbent and preparation method and application thereof | |
| CN101942107B (en) | Preparation method of protein-printed polymer of carboxymethyl chitosan and chitosan | |
| JPS62192172A (en) | Adsorbing body | |
| CN103252177A (en) | Glycosyl/sulfonated modified affiliative polymer hollow fiber separating membrane, and preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |